Editas Medicine Inc (NASDAQ: EDIT) is -27.34% lower on its value in year-to-date trading and has touched a low of $6.08 and a high of $11.91 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EDIT stock was last observed hovering at around $7.47 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $7.36, the stock is -16.32% and -10.51% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing -1.47% at the moment leaves the stock -14.63% off its SMA200. EDIT registered -0.81% loss for a year compared to 6-month loss of -6.24%. The firm has a 50-day simple moving average (SMA 50) of $4.04 and a 200-day simple moving average (SMA200) of -$1.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.76% gain in the last 1 month and extending the period to 3 months gives it a -28.82%, and is -4.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.66% over the week and 7.75% over the month.
Editas Medicine Inc (EDIT) has around 265 employees, a market worth around $602.12M and $78.12M in sales. Profit margin for the company is -196.13%. Distance from 52-week low is 21.05% and -38.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.03%).
Editas Medicine Inc quarterly earnings per share for the current quarter are estimated at -$0.67 with sales reaching $7.9M over the same period.The EPS is expected to shrink by -27.84% this year, but quarterly earnings will post -54.40% year-over-year. Quarterly sales are estimated to shrink -19.80% in year-over-year returns.
Editas Medicine Inc (EDIT) Top Institutional Holders
310 institutions hold shares in Editas Medicine Inc (EDIT), with institutional investors hold 76.30% of the company’s shares. The shares outstanding are 81.77M, and float is at 80.82M with Short Float at 16.73%. Institutions hold 75.61% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 8.17 million shares valued at $67.2 million. The investor’s holdings represent 10.00% of the EDIT Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 7.6 million shares valued at $62.51 million to account for 9.30% of the shares outstanding. The other top investors are State Street Corporation which holds 6.64 million shares representing 8.14% and valued at over $54.66 million, while Deep Track Capital, Lp holds 4.23% of the shares totaling 3.45 million with a market value of $28.42 million.
Editas Medicine Inc (EDIT) Insider Activity
The most recent transaction is an insider sale by O’Neill Gilmore Neil,the company’sCEO. SEC filings show that O’Neill Gilmore Neil sold 77,824 shares of the company’s common stock on Mar 05 ’24 at a price of $9.42 per share for a total of $0.73 million. Following the sale, the insider now owns 0.33 million shares.
Editas Medicine Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Mei Baisong (SVP, CHIEF MEDICAL OFFICER) sold a total of 20,327 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $9.42 per share for $0.19 million. Following the transaction, the insider now directly holds 0.14 million shares of the EDIT stock.
Still, SEC filings show that on Dec 05 ’23, Eaton Bruce (EVP, CBO AND CTO) disposed off 103 shares at an average price of $10.90 for $1122.0. The insider now directly holds 74,791 shares of Editas Medicine Inc (EDIT).
